Evidence map›Paper›PMID 39497094›Full record

ArticleJournal of translational medicine2024

PTBP1 crotonylation promotes colorectal cancer progression through alternative splicing-mediated upregulation of the PKM2 gene.

Jia-Yi Hou, Xiao-Ling Wang, Hai-Jiao Chang, Xi-Xing Wang, Shu-Lan Hao, Yu Gao, Gang Li, Li-Juan Gao, Fu-Peng Zhang, Zhi-Jie Wang and 3 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jia-Yi HouDepartment of Clinical Laboratory, Shanxi Provincial Academy of Traditional Chinese Medicine, Taiyuan, China.
Xiao-Ling WangDepartment of Clinical Laboratory, Shanxi Provincial Academy of Traditional Chinese Medicine, Taiyuan, China.
Hai-Jiao ChangDepartment of Clinical Laboratory, Shanxi Provincial Academy of Traditional Chinese Medicine, Taiyuan, China.
Xi-Xing WangDepartment of Oncology, Shanxi Provincial Academy of Traditional Chinese Medicine, Taiyuan, China.
Shu-Lan HaoDepartment of Oncology, Shanxi Provincial Academy of Traditional Chinese Medicine, Taiyuan, China.
Yu GaoDepartment of Oncology, Shanxi Provincial Academy of Traditional Chinese Medicine, Taiyuan, China.
Gang LiDepartment of General Surgery, Shanxi Provincial Academy of Traditional Chinese Medicine, Taiyuan, China.
Li-Juan GaoKey Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Key Laboratory of Cellular Physiology of Shanxi Province, and the Department of Physiology, Shanxi Medical University, Taiyuan, China.
Fu-Peng ZhangNational Clinical Research Base of Traditional Chinese Medicine, Shanxi Province Hospital of Traditional Chinese Medicine, Taiyuan, China.
Zhi-Jie WangDepartment of Oncology, Shanxi Provincial Academy of Traditional Chinese Medicine, Taiyuan, China.
Jian-Yun ShiKey Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Key Laboratory of Cellular Physiology of Shanxi Province, and the Department of Physiology, Shanxi Medical University, Taiyuan, China. shijianyun0418@126.com.
Ning LiDepartment of Gastrointestinal and Pancreatic Surgery & Hernia and Abdominal Surgery, Shanxi Provincial People's Hospital, Taiyuan, China. lining205310@126.com.
Ji-Min CaoKey Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Key Laboratory of Cellular Physiology of Shanxi Province, and the Department of Physiology, Shanxi Medical University, Taiyuan, China. caojimin@sxmu.edu.cn.ORCID 0000-0002-6546-555X

Funding

Basic Research Program of Shanxi Province 202203021212070Health Commission of Shanxi Province 2022123National Natural Science Foundation of China 82002063National Natural Science Foundation of China 82202622Shanxi Medical Key Science and Technology Project Plan of China 2020XM01Shanxi Traditional Chinese Medicine Administration Scientific Research Project 2023ZYYC004
6 · The paper itself

Abstract

backgroundAerobic glycolysis is a tumor cell phenotype and a hallmark in cancer research. The alternative splicing of the pyruvate kinase M (PKM) gene regulates the expressions of PKM1/2 isoforms and the aerobic glycolysis of tumors. Polypyrimidine tract binding protein (PTBP1) is critical in this process; however, its impact and underlying mechanisms in colorectal cancer (CRC) remain unclear. This study aimed to investigate the role of PTBP1 crotonylation in CRC progression.

methodsThe crotonylation levels of PTBP1 in human CRC tissues and cell lines were analyzed using crotonylation proteomics and immunoprecipitation. The main crotonylation sites were identified by immunoprecipitation and immunofluorescent staining. The glycolytic capacities of CRC cells were evaluated by measuring the glucose uptake, lactate production, extracellular acidification rate, and glycolytic proton efflux rate. The role and mechanism of PTBP1 crotonylation in PKM alternative splicing were determined by Western blot, quantitative real-time PCR (RT-qPCR), RNA immunoprecipitation, and immunoprecipitation. The effects of PTBP1 crotonylation on the behaviors of CRC cells and CRC progression were assessed using CCK-8, colony formation, cell invasion, wound healing assays, xenograft model construction, and immunohistochemistry.

resultsThe crotonylation level of PTBP1 was elevated in human CRC tissues compared to peritumor tissues. In CRC tissues and cells, PTBP1 was mainly crotonylated at K266 (PTBP1 K266-Cr), and lysine acetyltransferase 2B (KAT2B) acted as the crotonyltranferase. PTBP1 K266-Cr promoted glycolysis and lactic acid production, increasing the PKM2/PKM1 ratio in CRC tissues and cells. Mechanistically, PTBP1 K266-Cr enhanced the interaction of PTBP1 with heterogeneous nuclear ribonucleoprotein A1 and A2 (hnRNPA1/2), thus affecting the PKM alternative splicing. PTBP1 K266-Cr facilitated CRC cell proliferation, migration, and metastasis in vitro and in vivo. Pathologically, a high level of PTBP1 K266-Cr was associated with poor prognosis in CRC patients.

conclusionsCrotonylation of PTBP1 coordinates tumor cell glycolysis and promotes CRC progression by regulating PKM alternative splicing and increasing PKM2 expression.

Indexed as

Alternative SplicingCarrier ProteinsColorectal NeoplasmsDisease ProgressionGene Expression Regulation, NeoplasticHeterogeneous-Nuclear RibonucleoproteinsPolypyrimidine Tract-Binding ProteinThyroid Hormone-Binding ProteinsThyroid HormonesUp-RegulationAnimalsCell Line, TumorCell MovementCell ProliferationFemaleGlycolysisCarrier ProteinsHeterogeneous-Nuclear RibonucleoproteinsMembrane ProteinsPolypyrimidine Tract-Binding ProteinPTBP1 protein, humanThyroid Hormone-Binding ProteinsThyroid HormonesAlternative splicingColorectal cancerCrotonylationPKMPTBP1

Identifiers

PMID39497094
PMCPMC11536555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.